Nephros Statistics
Total Valuation
Nephros has a market cap or net worth of $33.10 million. The enterprise value is $28.77 million.
Important Dates
The next confirmed earnings date is Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nephros has 10.64 million shares outstanding. The number of shares has increased by 3.45% in one year.
| Current Share Class | 10.64M |
| Shares Outstanding | 10.64M |
| Shares Change (YoY) | +3.45% |
| Shares Change (QoQ) | +1.49% |
| Owned by Insiders (%) | 5.49% |
| Owned by Institutions (%) | 44.02% |
| Float | 9.45M |
Valuation Ratios
The trailing PE ratio is 28.27 and the forward PE ratio is 51.83.
| PE Ratio | 28.27 |
| Forward PE | 51.83 |
| PS Ratio | 1.76 |
| Forward PS | 1.58 |
| PB Ratio | 3.24 |
| P/TBV Ratio | 3.69 |
| P/FCF Ratio | 20.12 |
| P/OCF Ratio | 20.12 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 22.39, with an EV/FCF ratio of 17.49.
| EV / Earnings | 24.09 |
| EV / Sales | 1.53 |
| EV / EBITDA | 22.39 |
| EV / EBIT | 25.10 |
| EV / FCF | 17.49 |
Financial Position
The company has a current ratio of 4.06, with a Debt / Equity ratio of 0.10.
| Current Ratio | 4.06 |
| Quick Ratio | 2.82 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.61 |
| Debt / FCF | 0.65 |
| Interest Coverage | 1,146.00 |
Financial Efficiency
Return on equity (ROE) is 12.71% and return on invested capital (ROIC) is 19.14%.
| Return on Equity (ROE) | 12.71% |
| Return on Assets (ROA) | 5.76% |
| Return on Invested Capital (ROIC) | 19.14% |
| Return on Capital Employed (ROCE) | 10.54% |
| Weighted Average Cost of Capital (WACC) | 11.95% |
| Revenue Per Employee | $521,917 |
| Profits Per Employee | $33,167 |
| Employee Count | 36 |
| Asset Turnover | 1.51 |
| Inventory Turnover | 2.45 |
Taxes
In the past 12 months, Nephros has paid $12,000 in taxes.
| Income Tax | 12,000 |
| Effective Tax Rate | 1.00% |
Stock Price Statistics
The stock price has increased by +55.50% in the last 52 weeks. The beta is 1.47, so Nephros's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | +55.50% |
| 50-Day Moving Average | 3.28 |
| 200-Day Moving Average | 4.23 |
| Relative Strength Index (RSI) | 50.51 |
| Average Volume (20 Days) | 23,253 |
Short Selling Information
The latest short interest is 41,492, so 0.39% of the outstanding shares have been sold short.
| Short Interest | 41,492 |
| Short Previous Month | 46,667 |
| Short % of Shares Out | 0.39% |
| Short % of Float | 0.44% |
| Short Ratio (days to cover) | 0.96 |
Income Statement
In the last 12 months, Nephros had revenue of $18.79 million and earned $1.19 million in profits. Earnings per share was $0.11.
| Revenue | 18.79M |
| Gross Profit | 11.63M |
| Operating Income | 1.15M |
| Pretax Income | 1.21M |
| Net Income | 1.19M |
| EBITDA | 1.29M |
| EBIT | 1.15M |
| Earnings Per Share (EPS) | $0.11 |
Full Income StatementBalance Sheet
The company has $5.40 million in cash and $1.06 million in debt, with a net cash position of $4.34 million or $0.41 per share.
| Cash & Cash Equivalents | 5.40M |
| Total Debt | 1.06M |
| Net Cash | 4.34M |
| Net Cash Per Share | $0.41 |
| Equity (Book Value) | 10.20M |
| Book Value Per Share | 0.96 |
| Working Capital | 8.46M |
Full Balance SheetCash Flow
| Operating Cash Flow | 1.65M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 139,000 |
| Net Borrowing | -5,000 |
| Free Cash Flow | 1.65M |
| FCF Per Share | $0.15 |
Full Cash Flow StatementMargins
Gross margin is 61.87%, with operating and profit margins of 6.10% and 6.35%.
| Gross Margin | 61.87% |
| Operating Margin | 6.10% |
| Pretax Margin | 6.42% |
| Profit Margin | 6.35% |
| EBITDA Margin | 6.84% |
| EBIT Margin | 6.10% |
| FCF Margin | 8.76% |
Dividends & Yields
Nephros does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.45% |
| Shareholder Yield | -3.45% |
| Earnings Yield | 3.61% |
| FCF Yield | 4.97% |
Analyst Forecast
The average price target for Nephros is $6.00, which is 92.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 92.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 10, 2019. It was a reverse split with a ratio of 1:9.
| Last Split Date | Jul 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
Nephros has an Altman Z-Score of -6.09 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.09 |
| Piotroski F-Score | 6 |
